The withdrawal of rofecoxib

Pharmacoepidemiol Drug Saf. 2005 Mar;14(3):213-7. doi: 10.1002/pds.1077.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Aspirin / therapeutic use
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / prevention & control
  • Clinical Trials as Topic
  • Cyclooxygenase 2 Inhibitors / adverse effects*
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Death, Sudden, Cardiac / etiology
  • Drug Industry / economics
  • Humans
  • Lactones / adverse effects*
  • Lactones / therapeutic use
  • Naproxen / therapeutic use
  • Pharmacoepidemiology / methods
  • Pharmacoepidemiology / statistics & numerical data
  • Product Surveillance, Postmarketing / methods*
  • Product Surveillance, Postmarketing / standards
  • Product Surveillance, Postmarketing / statistics & numerical data
  • Sulfones / adverse effects*
  • Sulfones / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib
  • Naproxen
  • Aspirin